NIHR Biomedical Research Centre: Oxford

Enabling translational research through partnership

NIHR 20th Anniversary NIHR website
NIHR Biomedical Research Centre: Oxford
  • Home
  • About
    • About us
    • Impact
    • Our next BRC
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research
    • Research Overview
      • NIHR Clinical Research Facility
      • Ethics in the NIHR BRC: Oxford
      • Health Economics
      • Medical Statistics
    • Cancer
    • Cardiovascular Medicine
    • Digital Health from Hospital to Home
    • Gene and Cell Therapy
    • Genomic Medicine
    • Imaging
    • Inflammation across Tissues
    • Life-saving Vaccines
    • Metabolic Experimental Medicine
    • Modernising Medical Microbiology and Big Infection Diagnostics
      • Theme overview
      • Infections in Oxfordshire Database (IORD)
    • Musculoskeletal
    • Preventive Neurology
    • Respiratory Medicine
    • Surgical Innovation, Technology and Evaluation
    • Translational Data Science
  • Patient & Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training
  • Industry & Partnerships
  • News
  • Events
  • Videos

News

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

30 October 2026 · Listed under Cardiovascular Medicine, NIHR-BHF, Treatment to Prevention

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common heart rhythm disorder.

The study was led by the University of Oxford and supported by the NIHR Biomedical Research Centre: Oxford and the British Heart Foundation (BHF), with contributions from Baylor College of Medicine in the United States and other international partners.

Atrial fibrillation affects millions of people worldwide and significantly increases the risk of stroke, heart failure and premature death. Current treatments can help control heart rhythm and reduce complications, but there are no approved therapies that directly reverse atrial fibrosis, the structural scarring of the heart that can make atrial fibrillation progress and recur.

responsive image
A graphical abstract of the research published in the paper.

In the study, published in Nature Cardiovascular Research, researchers identified a small RNA molecule that regulates gene expression, miR-31-5p, as a key driver of atrial fibrosis. The team showed that miR-31-5p suppresses a natural process, mediated by the calcitonin receptor (CTR), that protects against scarring. This suppression promotes the activation of fibroblasts ( the main cell type in connective tissue), fibrosis and increased susceptibility to abnormal heart rhythms.

Using a highly selective RNA-based therapeutic approach, the researchers blocked the interaction between miR-31-5p and calcitonin receptor messenger RNA. In preclinical models, this not only prevented the development of fibrosis, but also reversed established atrial fibrosis and reduced problems with abnormal heart rhythms.

The findings identify the miR-31-5p/CTR pathway as a promising therapeutic target and provide proof-of-concept for a new class of precision RNA therapies aimed at treating the underlying structural changes that drive atrial fibrillation.

Prof Svetiana Reilly, Associate Professor of Cardiovascular Science at the University of Oxford and senior author of the Atrial Fibrosis study.
Professor Svetlana Reilly

Professor Svetlana Reilly, Associate Professor of Cardiovascular Science at the University of Oxford and senior author of the study, said: “Atrial fibrosis is a major unmet clinical problem in atrial fibrillation, and currently we have no therapies that directly target the scarring process itself. Our findings suggest that selective RNA-based therapies could offer a completely new way of treating the disease. Rather than simply controlling heart rhythm, we may be able to target and potentially reverse the structural changes that underpin arrhythmia progression.”

The research team say this research points to the potential to improve long-term outcomes for patients and enhance the effectiveness of existing treatments for atrial fibrillation. However, further work is required to identify and optimise a lead RNA therapeutic candidate, evaluate safety and efficacy in preclinical studies, and determine its suitability for future clinical development.

← Study of Bundibugyo Ebola candidate vaccine launched in Uganda
Breakthrough in non-invasive liver testing →

Other news

News Categories

News by Month

See all news
You are here: Home > Cardiovascular Medicine > Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Subscribe to the BRC Oxford Newsletter

Keep informed about the work of the BRC Oxford by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

BRC Oxford on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Disclaimer
  • Contact

Copyright © 2026 NIHR Biomedical Research Centre: Oxford